MYOCARDIAL EXTRACELLULAR VOLUME IS ELEVATED IN CANCER SURVIVORS TREATED WITH ANTHRACYCLINE-BASED CHEMOTHERAPY COMPARED TO CANCER-FREE PEERS AND NEWLY DIAGNOSED AND UNTREATED CANCER PATIENTS: A SINGLE-CENTER OBSERVATIONAL STUDY OF THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA) AND CARDIO-ONCOLOGY CARDIOVASCULAR MAGNETIC RESONANCE IMAGING STUDIES  by Jordan, Jennifer H. et al.
Non Invasive Imaging (Echocardiography, Nuclear, PET, MR and CT)
A1081
JACC March 17, 2015
Volume 65, Issue 10S
mYocArdiAl extrAcellulAr volume is elevAted in cAncer survivors treAted 
With AnthrAcYcline-BAsed chemotherAPY comPAred to cAncer-free Peers And 
neWlY diAgnosed And untreAted cAncer PAtients: A single-center oBservAtionAl 
studY of the multi-ethnic studY of Atherosclerosis (mesA) And cArdio-oncologY 
cArdiovAsculAr mAgnetic resonAnce imAging studies
Oral Contributions
Room 2
Monday, March 16, 2015, 11:00 a.m.-11:12 a.m.
Session Title: Highlighted Original Research: Non Invasive Imaging and the Year in Review
Abstract Category: 18.  Non Invasive Imaging: MR
Presentation Number: 913-04
Authors: Jennifer H. Jordan, Sujethra Vasu, Tim Morgan, Ralph D’Agostino, Giselle C. Melendez, Michael Hall, Craig Hamilton, Andrew Arai, 
Songtao Liu, Chia-Ying Liu, Joao Lima, David Bluemke, W. Hundley, Wake Forest University School of Medicine, Winston-Salem, NC, USA
Background:  Adult cancer survivors can have elevated cardiovascular magnetic resonance (CMR) left ventricular (LV) native T1 and 
extracellular volume (ECV) assessments. It remains undetermined whether these measures are related to the presence of cancer alone or 
cancer treatment.
methods:  We performed prospective measures of pre- and postcontrast T1 mapping and ECV in patients with breast cancer or a 
hematologic malignancy free of intracardiac cancer or metastases before (n=43) or 3.0±1.8 years after anthracycline chemotherapy (n=41). 
We compared these measures to 236 cancer-free participants from MESA Exam 5. We performed mixed model analyses to determine the 
dependency of T1 and ECV on demographics and cardiovascular (CV) risk factors.
results:  Native T1 and ECV were significantly elevated in cancer pre- and post-treatment subjects compared to cancer-free peers (Table 
1, p<0.0001). T1 was highest amongst pre-treatment cancer subjects; however, ECV was significantly higher in treated survivors. T1 and 
ECV was more elevated in survivors even after accounting for demographics, LV ejection fraction, and myocardial mass index (p<0.0001 
and p<0.01).
conclusion:  While elevated native T1 can represent a number of pathologies, chronically elevated ECV represents either remodeled 
intracellular to extracellular volume fractions or fibrosis. Elevated ECV appears associated with cancer treatment rather than cancer and 
may have implications in the higher CV events rates among cancer survivors.
